MX2012000752A - Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. - Google Patents

Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos.

Info

Publication number
MX2012000752A
MX2012000752A MX2012000752A MX2012000752A MX2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A
Authority
MX
Mexico
Prior art keywords
prodrug
opioid
amino acid
gastrointestinal side
opioids
Prior art date
Application number
MX2012000752A
Other languages
English (en)
Inventor
Bernard T Golding
Robert G Tyson
Richard Franklin
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of MX2012000752A publication Critical patent/MX2012000752A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se proporcionan profármacos ligados a carbamato de meptazinol y otros analgésicos opioides. La porción de profármaco puede comprender un aminoácido sencillo o péptido corto. Adicionalmente, la presente invención se refiere a métodos para reducir efectos colaterales gastrointestinales en un sujeto, los efectos colaterales gastronintestinales se asocian con la administración de un analgésico opioide. Los métodos comprenden administrar oralmente un profármaco opiolde o sal farmacéuticamente aceptable del mismo a un sujeto, en donde el profármaco opioide comprende un analgésico covalentemente enlazado a través de una ligadura carbamato a una porción de profármaco, y en donde durante la administración oral, el profármaco o sal farmacéuticamente aceptable minimiza al menos un efecto colateral gastrointestinal asociado con administración oral del analgésico opioide solo. También se proporcionan composiciones para uso con el método.
MX2012000752A 2009-07-17 2010-07-16 Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. MX2012000752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27118509P 2009-07-17 2009-07-17
PCT/IB2010/001747 WO2011007247A1 (en) 2009-07-17 2010-07-16 Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof

Publications (1)

Publication Number Publication Date
MX2012000752A true MX2012000752A (es) 2012-05-08

Family

ID=42768038

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000752A MX2012000752A (es) 2009-07-17 2010-07-16 Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos.

Country Status (10)

Country Link
US (2) US20110015182A1 (es)
EP (1) EP2453900A1 (es)
JP (1) JP2013527124A (es)
KR (1) KR20120060203A (es)
AU (1) AU2010272233A1 (es)
BR (1) BR112012001164A2 (es)
CA (1) CA2767987A1 (es)
MX (1) MX2012000752A (es)
RU (1) RU2012105460A (es)
WO (1) WO2011007247A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
SG179026A1 (en) 2009-09-08 2012-04-27 Signature Therapeutics Inc Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
DK2560486T3 (en) 2010-04-21 2019-02-04 Signature Therapeutics Inc COMPOSITIONS COMPREHENSIVE ENZYM-TENDABLE AMPHETAMINE PRODRUGS AND ITS INHIBITORS
JP6016810B2 (ja) 2011-01-11 2016-10-26 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物
BR112013022946A2 (pt) * 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
CA2834735C (en) 2011-04-29 2021-06-01 University Of Medicine And Dentistry Of New Jersey Use of nalbuphine for treating dyskinesia
TW201341356A (zh) * 2012-02-28 2013-10-16 皮拉馬爾企業有限公司 作為gpr促效劑之苯基烷酸衍生物
WO2015082932A1 (en) 2013-12-05 2015-06-11 The University Of Bath Novel opioid compounds and their uses
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス,インク. 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールtrpv1アゴニストのプロドラッグ
US10577346B2 (en) 2016-11-17 2020-03-03 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
CN113166051A (zh) 2018-07-27 2021-07-23 同心镇痛药物公司 酚类trpv1激动剂的聚乙二醇化前药
US11186585B2 (en) 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
WO2021029914A1 (en) 2019-08-11 2021-02-18 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19602970A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue 7,8- Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
US20070060500A1 (en) 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
IL163667A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
SG147485A1 (en) 2003-09-30 2008-11-28 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
EP1929030A2 (en) 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability
AU2007238858A1 (en) 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof

Also Published As

Publication number Publication date
WO2011007247A8 (en) 2012-07-19
US20120270847A1 (en) 2012-10-25
WO2011007247A1 (en) 2011-01-20
EP2453900A1 (en) 2012-05-23
CA2767987A1 (en) 2011-01-20
JP2013527124A (ja) 2013-06-27
KR20120060203A (ko) 2012-06-11
AU2010272233A1 (en) 2012-02-09
RU2012105460A (ru) 2013-08-27
US20110015182A1 (en) 2011-01-20
BR112012001164A2 (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
MX2012000752A (es) Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos.
WO2009092073A3 (en) Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MY149731A (en) Compounds
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2008024435A3 (en) Dendritic molecular intracellular transporters and methods of making and using same
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
NZ703564A (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
WO2012054500A3 (en) Compositions for drug administration
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1176318A1 (en) Injection device
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2011060104A3 (en) Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
GB2501219A (en) Orally bioavailable peptide drug compositions and methods thereof
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2012166891A3 (en) Mu-opioid receptor binding compounds
NZ600243A (en) Combination of theobromine with a decongestant and its use for the treatment of cough
MX2012001193A (es) Compuesto peptidico similar a motilina con capacidad de absorcion transmucosa impartida al mismo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal